Pregledni rad

Cannabis in oncology

Ana Tečić Vuger orcid.org/0000-0003-2203-161X ; Deparment of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Robert Šeparović orcid.org/0000-0002-4002-2699 ; Deparment of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Tajana Silovski orcid.org/0000-0002-4699-5432 ; Deparment of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mirjana Pavlović orcid.org/0000-0002-9633-064X ; Deparment of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Vesna Pavlica ; Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Sanda Vladimir Knežević ; Department of Pharmacognosy, Faculty of P harmacy, University of Zagreb, Croatia

Sažetak

Although today among oncology patients use of various preparations of complementary and alternative medicine is more and more frequent, there is unequivocal scientifi c base for their use. Among the often used preparations, especially in the treatment of cancer pain, is cannabis and its derivatives. Cannabinoids act on the endogenous cannabinoid system, with widespread receptors in the central nervous system and peripheral tissues. Although the pharmacology of the cannabinoids is still largely unknown, numerous of their eff ects were investigated. In oncology, studies have been conducted on the effect
of cannabinoids on nausea and vomiting during the oncological treatment, the cancer pain and neuropathy, on appetite and weight loss, and the impact on mood, depression and anxiety. It is also observed that some of the cannabinoids have antitumor, but also protumorous activity. There have been many diff erent side eff ects of cannabinoids detected, and in a smaller percentage also the development of addiction. Best known preparations nowadays are dronabinol, nabilon and nabiximol. At the moment, the evidence lack strenght, and large randomized clinical trials are required, which would confi rm predominatly positive results of the research.

Ključne riječi

CAM; cannabis; cannabinoids; CB1; CB2; cancer pain; cancer cachexia; chemotherapy induced nausea and vomiting; adverse eff ects; anticancer activity; protumorous eff ect; dronabinol; nabilon; nabiximol

Hrčak ID:

177241

URI

https://hrcak.srce.hr/177241

Datum izdavanja:

28.12.2016.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.570 *